BioSpectrum the business of Bio & Health Sciences

BCS to expand manufacturing of cyclotrons for research, radioisotope production & theranostics in India, Europe & USA

11 June 2024 | News

BCS plans to ship between 10-15 cyclotrons for global customers in 2024



Best Cyclotron Systems (BCS), a TeamBest Global Company (TBG) in the US, plans to expand its manufacturing operations in India, Europe, and the USA to produce hundreds of cyclotrons annually.

Within two years, BCS and TBG will have access to high-energy/high-current 70 MeV and 30 MeV proton beams, as well as 35 MeV alpha, deuteron, and proton multi-particle cyclotrons, and several low-energy proton cyclotrons for research, radioisotope production, and theranostics.

In 2024, BCS plans to ship between 10-15 cyclotrons for global customers. BCS is capable of and has demonstrated that it can manufacture low-energy cyclotrons with as high as 1000 micro amp current for proton beams.

BCS and TBG companies plan to produce the following cyclotrons and ion rapid cycling medical synchrotrons (iRCMS) for research, radioisotope production, theranostics, and for radiation therapy using proton beams from 70 MeV to 250 MeV variable energy and heavy ion therapy up to 400 MeV for Carbon: (1) 7.5 MeV, proton beam, B100, self-shielded cyclotron, (2) 9.5 MeV cyclotron, BG-95 for proton beam, self-shielded, (3) 11 MeV, self-shielded, proton beam cyclotron, (4) 15 MeV, high current up to 1000 micro amp current proton beam cyclotron, and (5) 25 MeV proton beam 1000 plus micro amp current cyclotron, 35 MeV adp, and 70 MeV adp alpha deuteron and proton beam cyclotron with 1000 plus micro amp for proton beam and 500 plus micro amp current for deuteron beam and 100 plus micro amp for alpha beam.